



OBJECTIVE: To explore drivers in people



living with type 2 diabetes (T2D) preferences for basal insulin treatment attributes to inform a discrete choice experiment (DCE).



KEY FINDINGS: Seven treatment attributes identified through a literature review were relevant to people living with T2D and had sufficient differentiation across insulin treatment profiles. Six of the attributes were reported to be important and influential to treatment decisions by interview participants.



INTERPRETATION: There are a wide range of factors people with T2D consider when making treatment decisions. Mode of administration, frequency of administration, dose timing and monitoring and risk of severe hypoglycaemia were identified as potentially important treatment differentiators to people living with T2D and were taken forward into the attributes and levels (A&L) grid incorporated into a DCE.



Background



- T2D presents a significant challenge to healthcare systems worldwide.¹
- Understanding preferences of people living with T2D for insulin treatment is critical to optimize treatment strategies, enhance satisfaction and improve overall clinical outcomes.²
- This study explored drivers in people living
- This study applied best practice guidelines^{3,4} for patient preference studies in a three-phase study design, **Phase 1: Targeted** with an advisory panel of clinical literature review experts and representatives of patient advocacy groups engaged at key points throughout the study (Figure 1).
- This poster presents the findings of the
- Targeted review of literature and the product labels of currently marketed basal insulins to identify concepts important to people living with T2D and differentiating product attributes

Synthesis of evidence to develop draft A&L grid

A&L grid development workshop to present literature review findings

Input from advisory panel

Revisions to draft A&L grid prior to conduct of qualitative interviews

Combined CE and CD qualitative interviews with N=10 Canadians with T2D to gain insight into the experience of T2D treatment and feedback on the draft A&L grid

PCR274

with T2D preferences for basal insulin treatment attributes to inform a DCE.

phase 1 (targeted literature review) and phase 2 (qualitative interviews). Phase 3 DCE findings are presented in a separate poster – PCR211.

Qualitative interview results presentation	Input from advisory panel				
Finalization of A&L grid ahead of quantitative online survey					
Phase 3: DCE					

Figure 1. Study design

Phase 2:

Qualitative

Interviews

A&L = Attributes and levels, CE = Concept elicitation, CD = Cognitive debriefing, T2D = Type 2 diabetes, DCE = Discrete choice experiment

Results: Literature review

Patient-focused literature

- Of the 1192 abstracts identified from searches of bibliographic databases, 10 eligible publications were reviewed.
- Identified concepts were categorized into themes across treatment concepts and health-related quality of life (HRQoL) impacts (Figure 2).

Treatment concepts

Clinical literature and product label review

- Data from six basal insulin products were assessed for differentiating attributes.
- Findings from the patient-focused literature and clinical review were compared to identify concepts which were both important to people living with T2D and

Dosage	Timing of dose	Side effects	Social functioning	Sociodemographic/clinical	differentiated across products (Figure 3) to inform the draft A&L grid.
 Adjusting insulin dose Double dosing Administering correct dose Ease of selecting correct dose Entire dose being taken 	 Timing of administration Convenience Forgetfulness 	 Renal failure Vision problems Weight gain Gastrointestinal effects 	 Friends and family negative opinions towards treatment Shame/embarrassment from public insulin injection Social rejection and reduction in 	 Barriers: Visually impaired, elderly, high BMI, lower SES, CVD, cultural and linguistic Facilitators: Poor physical health 	DillectudiationIninistration
 Reading dose correctly 	Medical professional advice	Injection site reactions	social activitiesBurden to family		And
•Correcting if over dialled	Clinician endorsement	 Pain, burning, bruising, scaring, swelling and bleeding 	•Loss of independence	Emotional wellbeing	Patient-relevant concepts
Frequency of administration	 Availability of treatment 	J J		•Acceptance, hopefulness	Mode of administration
• Fewer injections preferred		Risks	 Work Difficulty: Completing work responsibilities Coordinating treatment in 	Worry/concern Personal failure	Frequency of administration
• Difficult to integrate with other treatments		StrokeInsulin addiction			Timing of administration
Mode of administration					
Needle phobia	Efficacy	Ease of access	irregular working hours		Dosing Image: Constraint of the second sec
Preference for oral tablets	Preference for oral tablets ne and energy needed sire to avoid preparation• Improve blood sugar • Reduce complications• Supply shortageActiv • Cost• Prolong life • Prevention of hypoglycaemic events• Original • Accessibility due to cost• Original • Reduction	•Supply shortage Activities of daily living	Additional impacts to HRQoL	HbA1c reduction	
•Time and energy needed				Burdensome lifelong	Risk of severe hypoglycemic event
• Desire to avoid preparation		 Difficulty integrating insulin 	commitment	Injection site reactions	
 Preference for pens over vials/syringe 		 Accessibility due to cost 		 Negative and fatalistic views of insulin 	
• Ease of use of device		Insurance coverage Give u	• Give up activities		Side effects

Figure 2. Broad concepts and impacts identified in the targeted literature review of patient-focused literature BMI = Body mass index, SES = Socioeconomic status, CVD = Cardiovascular disease

Figure 3. Matrix of relevant concepts to people living with T2D and differentiating product attributes

Impacts to HRQoL


Results: Qualitative interviews

Study sample

- N=10 participants with T2D (aged 22-73; 50:50 female:male; 4.6-18 years since T2D diagnosis) were interviewed.
- A range of demographic and clinical characteristics were represented, available by scanning the QR code.

Concept elicitation

• Ten attributes of T2D treatments were reported by participants during the interviews (Figure 4).



Final A&L grid

- Edits were made to the A&L grid following the qualitative interviews:
 - Removed HbA1c attributes due to the lack of understanding of the levels and inflated importance compared to other attributes. Instead, HbA1c (as well as cost) were held as constant during the DCE, due to the likelihood they would have dominated treatment preferences;
 - Removed injection hold time due to it not being influential to people living with T2D;
 - Edited the wording to improve participant understanding.
- The final A&L grid implemented in the DCE is shown in Figure 5.




Figure 4. Treatment attributes discussed spontaneously and when probed during qualitative interviews **Note.** Attributes marked with an asterix (*) were included in the draft A&L grid and debriefed during the CD section of the interviews.

Cognitive debriefing

References

- Attributes included in the draft A&L grid were understood, important and influential to treatment decisions (scan QR code), except for:
 - Injection hold time which was not influential to the majority of participants;
 - Risk of a severe hypoglycemic event level wording which was was not understood by most participants.

	You manually record the dose you administered on	You manually record the dose you administered	The dose you administered is automatically
	paper	into an app	recorded in an app
Risk of a severe hypoglycemic event	ຊີ້ແຜ່ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ ເຊິ່ມຊີ້ແຜ່ນ	າຊີດຜູ້ແຜ່ນຊີດເຊິ່ນຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດ ຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດ ຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດ ຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນຊີດຜູ້ແຜ່ນ	
(insulin naïve	2 out of 100 insulin naïve patients who took	1 out of 100 insulin naïve patients who took this	
rates)	this insulin for a year experienced a	insulin for a year experienced a	No insulin naïve patients who took this insulin for
ruces,	severe hypoglycemic event	severe hypoglycemic event	a year experienced a severe hypoglycemic event
Risk of a severe hypoglycemic event (insulin			
experienced rates)	6 out of 100 patients who are on insulin took this insulin for a year experienced a severe hypoglycemic event	3 out of 100 patients who are on insulin took this insulin for a year experienced a severe hypoglycemic event	1 out of 100 patients who are on insulin took this insulin for a year experienced a severe hypoglycemic event

Figure 5. Final A&L grid implemented into the DCE

「「「「「「「「」」「「」「「」」「「」」
l Cardina da
98. S i i
11 31

Supplementary materials

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes research and clinical practice. 2022;183:109119.

- Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug discovery today. 2019;24(7):1324-1331
- US Food and Drug Administration. Patient-focused drug development: Collecting comprehensive and representative input Guidance for industry, Food and Drug Administration staff, and other stakeholders. 2020; 3.
- 4. PREFER I. "PREFER Recommendations. Why, when and how to assess and use patient preferences in medical product decision-making. 2022.